
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.7M shares of common stock. The company is not selling any
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GOSS | Gossamer Bio | 10.98 | -228.44 | -95.41% |
| Name | Price | % Change | |
|---|---|---|---|
| $10.98 | -95.41% |

This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.7M shares of common stock. The company is not selling any

Piper Sandler lowered the firm’s price target on Gossamer Bio (GOSS) to $96 from $120 and keeps an Overweight rating on the shares. The firm notes the company reported Q3

Reports Q3 revenue $38.4M, consensus $12.2M. “Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH,” said Faheem

Defendants Gossamer Bio, Inc.($GOSS) and two of its executives have asked a federal court to dismiss a securities fraud lawsuit tied to the company’s development of seralutinib, an investigational inhaled

Gossamer Bio ( ($GOSS) ) has issued an announcement. At a special meeting held on October 27, 2026, Gossamer Bio stockholders approved a proposal under Nasdaq Listing Rules 5635(c) and

Biotech & Pharma Analysts discuss pulmonary arterial hypertension (PAH) and PAH associated with interstitial lung disease (PH-ILD) (relevant companies GOSS IKT INSM LQDA ROIV UTHR) on an Analyst/Industry conference call

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Chardan analyst Andreas Argyrides initiated coverage of Gossamer Bio (GOSS) with a Buy rating and $160 price target The firm says the bull case centers around FDA approval of seralutinib.

The latest update is out from Gossamer Bio ( ($GOSS) ). On September 25, 2026, Gossamer Bio, Inc. reported that it had regained compliance with Nasdaq’s minimum bid price requirement

U.N. General Assembly standoff pitting President Trump’s threat to annihilate Iran against a defiant tone from Iranian President that his country will not bow down to pressure reverberated across financial
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 12, 2027TBA | $67.10M | $-2.51 | $0.00 | -0.02 | -0.31 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.